| |
|
|
|
|
|
|
|||
|
LA Miles, JP Burnier, MS Verlander, M Goodman, AJ Kleiss and JH Griffin
3-Hydroxypropyl flufenamide (Flu-HPA) is one of a series of flufenamic acid
derivatives that enhances blood clot lysis in vitro. Studies of possible
mechanisms of action of Flu-HPA were undertaken. The profibrinolytic
activity of Flu-HPA in clot lysis assays was found to be dependent on
plasminogen. The influence of Flu-HPA on the ability of purified alpha
2-antiplasmin to inhibit purified plasmin was studied. Plasmin activity was
determined using 125I-fibrin plates or the spectrophotometric tripeptide
substrate, Val-Leu-Lys-paranitroanilide. At Flu-HPA concentrations greater
than 1 mM, the inhibitory activity of alpha 2-antiplasmin was abolished in
a time-dependent and concentration- dependent manner. The influence of
Flu-HPA on the ability of purified Cl inhibitor to inhibit purified plasma
kallikrein and beta-Factor XIIa was also studied. Cl inhibitor activity was
abolished by Flu-HPA at concentrations greater than 2 mM. Notably, Flu-HPA
up to 60 mM did not affect the amidolytic activities of plasmin,
kallikrein, or beta-Factor XIIa. Flu-HPA did not release enzyme activity
from preformed complexes of either alpha 2-antiplasmin and plasmin of Cl
inhibitor and kallikrein. A water-soluble derivative of flufenamic acid,
N-flufenamyl- glutamic acid, also inactivated alpha 2-antiplasm and Cl
inhibitor. This inactivation was shown to be reversible. These results
indicate that synthetic fibrinolytic compounds such as flufenamic acid
derivatives may promote fibrinolysis by directly inactivating alpha 2-
antiplasmin and Cl inhibitor.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1981 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||